The role of lonidamine in the treatment of breast cancer patients.
Rosso
R
R
Divisione di Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Gardin
G
G
Pronzato
P
P
Camoriano
A
A
Merlini
L
L
Naso
C
C
Rosso
M
M
Barone
C
C
Nascimben
O
O
Ianniello
G
G
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007191:Indazoles / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity*; D008875:Middle Aged; D016019:Survival Analysis
D000970:Antineoplastic Agents; D007191:Indazoles; D015251:Epirubicin; D003520:Cyclophosphamide; C016371:lonidamine